非布司他相关药疹文献分析

Literature analysis of febuxostat-associated drug eruptions

目的 :探讨非布司他相关药疹的发生规律和特点,为临床合理用药提供参考。方法 :检索CNKI、万方、维普、Pubmed、Medline数据库,收集国内外非布司他相关皮疹的案例报道并进行回顾性分析。结果 :共收集文献报道10篇,获取相关病例11例。非布司他相关药疹多发生于> 60岁的患者(90.91%),且皮疹多在用药后1周内发生,皮疹形态多样,可累及全身。病例报道中患者多有别嘌醇过敏史(81.82%),慢性肾功能不全(63.64%),在3例接受HLA-B5801检测的患者中有2例呈阳性(66.67%)。药疹在停药后均好转或痊愈。结论 :临床在使用非布司他过程中需加强皮疹相关监测,尤其是在用药后1周内,另对于老年患者、有别嘌醇过敏史或HLA-B5801阳性、中度至重度肾功能不全的患者应更为关注其药疹情况。

Objective:To investigate the general patterns and characteristics of drug eruptions induced by febuxostat.Methods:The case reports of febuxostat-associated drug eruptions collected from Wanfang database,VIP,CNKI,PubMed and Medline were retrospectively analyzed.Results:A total of 10 reports involving 11 cases were collected and analyzed.Febuxostatinduced drug eruptions occurred in the patients over 60 years old(90.91%)and rashes easily occurred within one week after medication.The rashes varied in shapes and could even invaded the whole body.Most patients in these cases were allopurinolintolerant(81.82%)or chronic renal insufficiency(63.64%).Two of the three patients who received HLA-B5801 test were positive(66.67%).The drug eruptions were improved or healed after stopping the drug.Conclusion:Physicians should pay great attention to febuxostat-induced rash,especially in the first week after medication.The occurrence of febuxostat-induced drug eruptions should be alerted in elderly patients with positive AHS or HLA-B5801,moderate or severe renal insufficiency.